Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 03/04/2019
Entire Document
 


Case 18-10518-KG     Doc 958     Filed 02/28/19     Page 6 of 11

 

In re: Orexigen Therapeutics, Inc.

   Case No. 18-10518 (KG)

Debtor

   Reporting Period: January 1, 2019 - January 31, 2019

 

MOR - 1b

Schedule of Debtor Bank Account Balances (1)

For the Period: January 1, 2019 - January 31, 2019

(Unaudited)

 

 $ USD ‘000s

 Debtor

   Bank    Last Four Digits
Account No.
    Account Description       Beginning
Balance
1/1/2019
    Ending 
Balance 
    1/31/2019 
 

 

 

 Orexigen Therapeutics, Inc.

  

Silicon Valley Bank

     6813    

General checking

    $ -       $  

 Orexigen Therapeutics, Inc.

  

Silicon Valley Bank

     1180    

Zero-balance lockbox

          –   

 Orexigen Therapeutics, Inc.

  

Silicon Valley Bank

     3036    

Sweep account

    26,927       26,624   

 Orexigen Therapeutics, Inc.

  

Silicon Valley Bank

     7307    

Utility adequate assurance

           

 Orexigen Therapeutics, Inc.

  

Silicon Valley Bank

     5177    

Collateral

    100       100   
         

 

 

 

 Total Bank Account Balances

            $ 27,027       $ 26,724   
         

 

 

 

Notes:

 

(1) The Consolidated Schedule of Cash Receipts and Disbursements (MOR-1) and Schedule of Disbursements by Debtor Entity (MOR-1a) represent book balances while MOR-1b represents bank balances. The balances differ primarily due to the bank’s delayed recording of intrabank activity between the general checking and sweep accounts.